The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Biology of Prostate-Specific Antigen
Abstract
Prostate-specific antigen (PSA) is an androgen-regulated serine protease produced by both prostate epithelial cells and prostate cancer (PCa) and is the most commonly used serum marker for cancer. It is a member of the tissue kallikrein family, some of the members of which are also prostate specific. PSA is a major protein in semen, where its function is to cleave semenogelins in the seminal coagulum. PSA is secreted into prostatic ducts as an inactive 244–amino acid proenzyme (proPSA) that is activated by cleavage of seven N-terminal amino acids. PSA that enters the circulation intact is rapidly bound by protease inhibitors, primarily alpha1-antichymotrypsin, although a fraction is inactivated in the lumen by proteolysis and circulates as free PSA. This proteolytic inactivation, as well as the cleavage of proPSA to PSA, is less efficient in PCa. Serum total PSA levels are increased in PCa, and PSA screening has dramatically altered PCa presentation and management. Unfortunately, although high PSA levels are predictive of advanced PCa, a large fraction of organ-confined cancers present with much lower total PSA values that overlap those levels found in men without PCa. Measurement of free versus total PSA can increase specificity for PCa, and tests under development to measure forms of proPSA may further enhance the ability to detect early-stage PCa. PSA is also widely used to monitor responses to therapy and is under investigation as a therapeutic target. Finally, recent data indicate that there may be additional roles for PSA in the pathogenesis of PCa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171501 · Cited by 2,451
Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Bioregulation of kinins: kallikreins, kininogens, and kininases.
Bhoola, K. D., Figueroa, C. D., & Worthy, K. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00058-4 · Cited by 1,744
Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., et al. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)35233-3 · Cited by 1,592
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Oesterling, J. E. (1993) · JAMA · doi:10.1001/jama.270.7.860 · Cited by 1,266
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Self-citationCatalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., et al. (1998) · JAMA · doi:10.1001/jama.279.19.1542 · Cited by 1,162
Consensus statement: Guidelines for PSA following radiation therapy1
AMERICANSOCIETYFORTHERAPEUTICR (1997) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00002-3 · Cited by 1,151
Catalona, W. J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510080052031 · Cited by 998
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationStenman, U., Leinonen, J., Alfthan, H. V., et al. (1991) · PubMed · Cited by 930
Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin
Lilja, H., Christensson, A., Dahlén, U., Matikainen, M. T., Nilsson, O., Pettersson, K., & Lövgren, T. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.9.1618 · Cited by 910
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Oesterling, J. E. (1993) · JAMA · doi:10.1001/jama.1993.03510070082041 · Cited by 807
Benson, M. C., Whang, I. S., Pantuck, A. J., Ring, K. S., Kaplan, S. A., Olsson, C. A., & Cooner, W. H. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37393-7 · Cited by 763
Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., & Wilson, E. M. (2001) · PubMed · Cited by 708
The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease*
Yousef, G. M., & Diamandis, E. P. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0424 · Cited by 675
Screening for Prostatic Carcinoma with Prostate Specific Antigen
Brawer, M. K., CHETNER, M. P., Beatie, J., Büchner, D. M., Vessella, R. L., & Lange, P. H. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37401-3 · Cited by 612
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 596
Self-citationPROSTATE-SPECIFIC ANTIGEN AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY
Pound, C. R., Partin, A. W., Epstein, J. I., & Walsh, P. C. (1997) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70386-4 · Cited by 588
Rodríguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., & Henderson, D. (1997) · PubMed · Cited by 584
Human prostate-specific antigen: structural and functional similarity with serine proteases.
Watt, K. W., Lee, P. J., M'Timkulu, T., Chan, W. P., & Loor, R. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.10.3166 · Cited by 560
Gohagan, J. K., Prorok, P. C., Hayes, R. B., & Kramer, B.-S. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00097-0 · Cited by 544
Cohen, P. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1046 · Cited by 497
Clinical use of Prostate Specific Antigen in Patients with Prostate Cancer
Hudson, M. A., Bahnson, R. R., & Catalona, W. J. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)38972-3 · Cited by 491
The Promoter of the Prostate-Specific Antigen Gene Contains a Functional Androgen Responsive Element
Riegman, P. H. J., Vlietstra, R. J., van der Korput, J. A. G. M., Brinkmann, A. O., & Trapman, J. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-12-1921 · Cited by 451
Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men
Morgan, T. O., Jacobsen, S. J., McCarthy, W. F., Jacobson, D. J., McLeod, D. G., & Moul, J. W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608013350502 · Cited by 412
Cleutjens, K. B. J. M., van Eekelen, C. C. E. M., van der Korput, H. A. G. M., Brinkmann, A. O., & Trapman, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.6379 · Cited by 406
Lilja, H., Oldbring, J., Rannevik, G., & Laurell, C. B. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113070 · Cited by 395
Molecular cloning of human prostate specific antigen cDNA
Lundwall, Å., & Lilja, H. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80078-9 · Cited by 391
Androgen receptors in endocrine‐therapy‐resistant human prostate cancer
van der Kwast, T. H., Schalken, J., de Winter, J. A. R., van Vroonhoven, J. C. C., Mulder, E., Boersma, W., & Trapman, J. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910480206 · Cited by 386
Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V, Schwartz, M., & Fossa, S. D. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.607 · Cited by 385
Cleutjens, K. B. J. M., van der Korput, H. A. G. M., van Eekelen, C. C. E. M., van Rooij, H. C. J., Faber, P. W., & Trapman, J. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.2.9883 · Cited by 374
Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia
Mantzoros, C., Tzonou, A., Signorello, L., Stampfer, M., Trichopoulos, D., & Adami, H.-O. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.520 · Cited by 366
PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCER
MOUL, J. W. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67511-8 · Cited by 350
Serum Prostate Specific Antigen as Pre-Screening Test for Prostate Cancer
Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.-L., & Emond, J. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37402-5 · Cited by 337
Catalona, W. J., Southwick, P. C., Slawin, K. M., Partin, A. W., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., Walsh, P. C., Scardino, P. T., et al. (2000) · Urology · doi:10.1016/s0090-4295(00)00637-3 · Cited by 335
Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer
Schuur, E. R., Henderson, G. A., Kmetec, L. A., Miller, J. D., Lamparski, H. G., & Henderson, D. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.12.7043 · Cited by 305
Eder, J. P., Kantoff, P. W., Röper, K., Xu, G., Bubley, G. J., Boyden, J., Gritz, L. R., Mazzara, G. P., Oh, W. K., Arlen, P. M., et al. (2000) · PubMed · Cited by 294
Self-citationOettgen, P., Finger, E., Sun, Z., Akbarali, Y., Thamrongsak, U., Boltax, J., Grall, F., Dube, A., Weiss, A., Brown, L., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.2.1216 · Cited by 268
Cohen, P., Peehl, D. M., Graves, H. C. B., & Rosenfeld, R. G. (1994) · Journal of Endocrinology · doi:10.1677/joe.0.1420407 · Cited by 268
Carter, H. B., Morrell, C. H., Pearson, J. D., et al. (1992) · PubMed · Cited by 240
Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.
Webber, M. M., Waghray, A., & Bello, D. (1995) · PubMed · Cited by 224
Nelson, P. S., Gan, L., Ferguson, C., Moss, P., Gelinas, R., Hood, L., & Wang, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3114 · Cited by 216
Smith, D. C., Dunn, R. L., Strawderman, M. S., & Pienta, K. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1835 · Cited by 215
Characterization of the Precursor of Prostate-specific Antigen
Takayama, T. K., Fujikawa, K., & Davie, E. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21582 · Cited by 214
Antiangiogenic Activity of Prostate-Specific Antigen
Fortier, A. H., Nelson, B. J., Grella, D. K., & Holaday, J. W. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.19.1635 · Cited by 210
Kumar, A., Mikolajczyk, S. D., Goel, A. S., Millar, L. S., & Saedi, M. S. (1997) · PubMed · Cited by 194
Cramer, S. D., Chen, Z., & Peehl, D. M. (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)65919-6 · Cited by 192
Use of human prostate-specific antigen in monitoring prostate cancer.
Kuriyama, M., Wang, M. C., Lee, C., Papsidero, L. D., Killian, C. S., Inaji, H., Slack, N. H., Nishiura, T., Murphy, G. P., & Chu, T. M. (1981) · PubMed · Cited by 192
Murtha, P., Tindall, D. J., & Young, C. Y. F. (1993) · Biochemistry · doi:10.1021/bi00076a020 · Cited by 182
Tissue-specific and hormonal regulations of human prostate-specific glandular kallikrein
Young, C. Y. F., Andrews, P. E., Montgomery, B. T., & Tindall, D. J. (1992) · Biochemistry · doi:10.1021/bi00118a026 · Cited by 179
Killian, C. S., Corral, D. A., Kawinski, E., & Constantine, R. I. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1506 · Cited by 178
CHRISTENSSON, A., & LILJA, H. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb18597.x · Cited by 170
A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum
Mikolajczyk, S. D., Grauer, L. S., Millar, L. S., et al. (1997) · Urology · doi:10.1016/s0090-4295(97)00449-4 · Cited by 167
Scher, H. I., Kelly, W. M. K., Zhang, Z.-F., Ouyang, P., Sun, M., Schwartz, M., Ding, C., Wang, W., Horak, I. D., & Kremer, A. B. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.3.244 · Cited by 165
Miller, J. I., Ahmann, F. R., Drach, G. W., Emerson, S. S., & Bottaccini, M. R. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37432-3 · Cited by 163
Huang, W., Shostak, Y., Tarr, P. T., Sawyers, C. L., & Carey, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25756 · Cited by 163
Latham, J. P. F., Searle, P. F., Mautner, V., et al. (2000) · PubMed · Cited by 163
Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
Heidtmann, H.-H., Nettelbeck, D. M., Mingels, A., Jäger, R., Welker, H.-G., & Kontermann, R. E. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6692167 · Cited by 148
Use of nude mouse xenograft models in prostate cancer research
van Weerden, W. M., & Romijn, J. C. (2000) · The Prostate · doi:10.1002/1097-0045(20000601)43:4<303::aid-pros10>3.0.co;2-v · Cited by 142
Gotoh, A., Ko, S.-C., Shirakawa, T., Cheon, J., Kao, C. H., Miyamoto, T., Gardner, T. A., Ho, L., Cleutjens, C. B. J. M., Trapman, J., et al. (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)63094-5 · Cited by 120
Denmeade, S. R., Sokoll, L. J., Chan, D. W., et al. (2001) · The Prostate · doi:10.1002/pros.1075 · Cited by 110
Measurement of Prostate‐Specific Antigen and Human Glandular Kallikrein 2 in Different Body Fluids
Lövgren, J., Valtonen‐André, C., Maršál, K., LIUA, H., & Lundwall, Å. (1999) · Journal of Andrology · doi:10.1002/j.1939-4640.1999.tb02528.x · Cited by 108
Stephan, C., Jung, K., Lein, M., Sinha, P. K., Schnorr, D., & Loening, S. A. (2000) · PubMed · Cited by 106
Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer.
Critz, F. A., Levinson, A., Williams, W. H., & Holladay, D. A. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2893 · Cited by 82
Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4.
Gm, Y., Ly, L., & Diamandis, E. P. (1999) · PubMed · Cited by 80
The definition of biochemical failure in patients treated with definitive radiotherapy
Kattan, M. W., Fearn, P., Leibel, S. A., & Potters, L. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01359-6 · Cited by 71
Pretlow, T. G., Pretlow, T. P., Yang, B., Kaetzel, C. S., Delmoro, C. M., Kamis, S. M., Bodner, D. R., Kursh, E. D., Resnick, M. I., & Bradley, E. L. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490503 · Cited by 62
Sun, Z. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.16.3318 · Cited by 57
Zhang, S., Murtha, P. E., & Young, C. Y. F. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6197 · Cited by 51
Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues
Howarth, D., Aronson, I., & Diamandis, E. P. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.280 · Cited by 51
Human kallikrein hK2 has low kininogenase activity while prostate-specific antigen (hK3) has none
Deperthes, D., Marceau, F., Frenette, G., Lazure, C., Tremblay, R. R., & Dubé, J. Y. (1997) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(97)00135-0 · Cited by 41
TREATMENT OF METASTATIC PROSTATE CANCER
Bubley, G. J., & Balk, S. P. (1996) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70363-4 · Cited by 19
Self-citation
Cited by
Human and mouse proteases: a comparative genomic approach
Puente, X. S., Sánchez, L. M., Overall, C. M., & López-Otín, C. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1111 · Cited by 943
Wang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 687
Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology
Schmidt, H. D., Shelton, R. C., & Duman, R. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.151 · Cited by 474
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003180 · Cited by 472
Electrical biosensors and the label free detection of protein disease biomarkers
Luo, X., & Davis, J. J. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60077g · Cited by 460
Metadata
- Authors
- Balk, S. P., Ko, Y.-J., & Bubley, G. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-01-15
- Volume
- 21
- Issue
- 2
- Pages
- 383-391
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2122680090
- Cited by
- 718
- References
- 78
- FWCI
- 23.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.